Table 1 Clinical and pathological characteristics of 181 invasive breast tumors at the time of diagnosis
From: Amplification of HER2 is a marker for global genomic instability
| Â | HER2 amplified (n = 39) | HER2 negative (n = 142) | P-valuea |
|---|---|---|---|
Menopausal Status | Â | Â | Â |
Pre (<50 years) | 31% | 31% | NS |
Menopausal (≥ 50 years) | 69% | 69% |  |
Tumor Type | Â | Â | Â |
Infiltrating ductal | 84% | 73% | NS |
Infiltrating lobular | 8% | 16% | Â |
Mixed ductal and lobular | 5% | 5% | Â |
Other | 3% | 6% | Â |
Tumor Grade | Â | Â | Â |
Well (Grade 1) | 11% | 41% | P < 0.0001b |
Moderate (Grade 2) | 26% | 36% | Â |
Poor (Grade 3) | 63% | 23% | Â |
Hormone Receptor Status | Â | Â | P < 0.05c |
ER+/PR+ | 53% | 63% | Â |
ER+/PR- | 11% | 17% | Â |
ER-/PR+ | 0% | 3% | Â |
ER-/PR- | 36% | 17% | Â |
Lymph Node Status | Â | Â | NS |
Negative | 47% | 53% | Â |
Positive | 53% | 47% | Â |
TNM Stage | Â | Â | NS |
Stage I | 36% | 47% | Â |
Stage II | 40% | 35% | Â |
Stage III | 21% | 16% | Â |
Stage IV | 3% | 2% | Â |
HER2 – IHC |  |  | P < 0.0005d |
0+ | 0% | 17% | Â |
1+ | 6% | 33% | Â |
2+ | 17% | 49% | Â |
3+ | 77% | 1% | Â |